Bausch Health Companies Inc. (NYSE:BHC - Free Report) - Analysts at Zacks Research cut their Q2 2025 earnings per share estimates for shares of Bausch Health Companies in a research note issued on Wednesday, May 21st. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.99 per share for the quarter, down from their prior estimate of $1.05. The consensus estimate for Bausch Health Companies' current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2025 earnings at $1.19 EPS, FY2025 earnings at $3.83 EPS, Q1 2026 earnings at $0.88 EPS, FY2026 earnings at $4.11 EPS and FY2027 earnings at $4.87 EPS.
Other equities research analysts also recently issued reports about the stock. Jefferies Financial Group reiterated a "hold" rating and set a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Royal Bank of Canada increased their price objective on Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. Finally, Wall Street Zen downgraded Bausch Health Companies from a "buy" rating to a "hold" rating in a report on Saturday, May 10th. One investment analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $7.42.
View Our Latest Analysis on Bausch Health Companies
Bausch Health Companies Trading Down 1.4%
BHC traded down $0.07 on Monday, reaching $4.55. The stock had a trading volume of 68,064 shares, compared to its average volume of 2,551,435. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -37.79, a price-to-earnings-growth ratio of 0.37 and a beta of 0.34. The firm has a 50-day moving average of $5.10 and a 200-day moving average of $6.69. Bausch Health Companies has a fifty-two week low of $3.96 and a fifty-two week high of $9.85.
Institutional Trading of Bausch Health Companies
Hedge funds have recently modified their holdings of the stock. SBI Securities Co. Ltd. raised its stake in Bausch Health Companies by 244.2% during the 1st quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock worth $27,000 after buying an additional 3,001 shares during the period. Cary Street Partners Financial LLC acquired a new position in shares of Bausch Health Companies during the first quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Bausch Health Companies in the 1st quarter worth $27,000. Mountain Hill Investment Partners Corp. acquired a new stake in Bausch Health Companies in the 4th quarter valued at $56,000. Finally, Wealthquest Corp bought a new stake in Bausch Health Companies during the 1st quarter valued at $58,000. Institutional investors own 78.65% of the company's stock.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
See Also
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
